Drugs / AK102
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04169386 | May → Nov 2018 | hyperlipidemia | Akeso | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04358432 | May 2020 → Feb 2021 | hyperlipidemia | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT04173793 | Nov 2019 → Sep 2022 | familial hypercholesterolemia | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT04173403 | Nov 2019 → Feb 2023 | hyperlipidemia | Akeso | Completed | No outcome recorded |
| Phase 2 | NCT03933293 | May 2019 → Mar 2021 | homozygous familial hypercholesterolemia | Akeso | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05260411 | Jan → Dec 2022 | hyperlipidemia | Akeso | Completed | No outcome recorded |
| Phase 3 | NCT05255458 | Nov 2021 → Jan 2023 | hyperlipidemia | Akeso | Completed | No outcome recorded |
| Phase 3 | NCT05255094 | Nov 2021 → Jun 2022 | hyperlipidemia | Akeso | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-28 | Akeso | 康方生物PCSK9单抗（AK102）已开展治疗高胆固醇血症的III期临床研究 akesobio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05260411 ↗ |
| Action | Inhibit | “PCSK9 inhibitor AK102” NCT03933293 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9)” NCT05255094 ↗ |
| Route | Subcutaneous | “AK102 single dose administered subcutaneously” NCT04169386 ↗ |
| Target | PCSK9 | “PCSK9 inhibitor AK102” NCT03933293 ↗ |